Navigation Links
Advanced Prenatal Therapeutics - Using Targeted Apheresis to Treat Preeclampsia
Date:5/22/2013

LAGUNA HILLS, Calif., May 22, 2013 /PRNewswire/ -- Advanced Prenatal Therapeutics (APT), a privately held company, is developing a medical device that will help alleviate the high blood pressure and other symptoms associated with preeclampsia. APT's targeted apheresis cartridge is expected to be the first medical device specifically designed to treat preeclampsia, a leading cause of maternal and fetal death.

Every year, preeclampsia affects approximately 300,000 pregnant women in the United States. It is characterized by high blood pressure and proteinuria induced by pregnancy. Treatment currently consists of bed rest and other supportive measures such as closely monitoring the patient. To avoid the life-threatening complications of preeclampsia, the baby is often delivered prematurely at the first signs of distress. Unfortunately, premature delivery is also a primary cause of infant death and life-long disabilities.

APT's patent-pending technology uses a process called "targeted apheresis" to remove harmful proteins that are involved in the disease process from the mother's blood while preserving the blood components that are healthy and viable. In preeclampsia, the placenta produces harmful proteins that prevent the action of certain growth factors that regulate blood vessel growth. These harmful proteins are believed to contribute to maternal high blood pressure and other symptoms of preeclampsia. Removal of these harmful proteins using targeted apheresis could alleviate maternal high blood pressure and other symptoms of preeclampsia. It could also help extend the duration of the pregnancy – and perhaps even lead to healthy babies born on time.

Apheresis is a common procedure similar to kidney dialysis in which the patient's blood is passed through a device that separates and removes a particular substance from the blood and returns the cleaned blood back to the patient. "Preeclampsia is a completely unmet medical need," explains Dr. James Smith , President and CEO of APT. "We are extremely proud to be developing what we expect to be a very viable and low-risk therapy for preeclampsia."

About Advanced Prenatal Therapeutics, Inc. (www.advancedprenatal.com) Advanced Prenatal Therapeutics, Inc.'s mission is to develop treatments for preeclampsia that will safely prolong pregnancy. To accomplish this goal, APT is developing a novel therapeutic device for preeclampsia that specifically removes harmful factors from the mother's blood. This press release may contain forward-looking statements. There can be no assurance that development efforts will succeed, or that the novel therapeutic products will receive regulatory clearance, or achieve commercial success.

Investor Relations:
Dan Thiel
949.340.7261
dthiel@advancedprenatal.com


'/>"/>
SOURCE Advanced Prenatal Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardium Exhibiting Its New FDA-Cleared Excellagen® At The 2012 Spring Symposium Of Advanced Wound Care
2. VeriStrat® Test Results Correlate with Survival Outcomes in Advanced Lung Cancer
3. Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinsons Disease
4. Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
5. Endocrinology Market to 2018 - Advanced Injection Devices for Growth Hormone and Somatostatin will Improve Ease of Use for Patients
6. Reduction of Chemotherapy and PET-Guided Radiotherapy in Advanced-Stage Hodgkin Lymphoma: the GHSG HD15 Trial
7. Abbott Presents Results of Clinical Studies Evaluating Its Investigational Treatment for Advanced Parkinsons Disease
8. PeriGen, Inc. Introduces New, Advanced Perinatal System at National Perinatal Nursing Convention
9. Advanced Radiotherapy Techniques Explored at Educational Events in India
10. Biosimilars in Emerging Economies - Advanced Recombinant Technology Platforms and Low Cost Manufacturing Put India and China at a Strategic Advantage in Biosimilar Production
11. Health Diagnostic Laboratory, Inc. (HDL, Inc.) Brings Advanced Testing to Capitol Hill, Discusses Health Care Cost Savings and Quality Improvement Potential
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... for their devotion to personalized service, SMP Pharmacy Solutions announces ... the South Florida Business Journal,s 50 Fastest-Growing Companies, and listed ... national specialty pharmacy has found its niche.  To that end, ... honored by SFBJ as the 2017 Power Leader in Health ... his award in October, Bardisa said of the three achievements, ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... The American Board ... become its next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon ... beginning July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor Janice ... of cardiovascular diseases during the 15th Annual Women’s Health Conference. The SIU ...
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th ... Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, ... The fun run is geared towards children of all ages; it is a non-competitive, ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
Breaking Medicine News(10 mins):